ArticleMolecular genetics & genomic medicine2026
Novel Variants in KMT2C Further Support a Neurodevelopmental Disorder Distinct From Kleefstra and Kabuki Syndromes.
Article in Molecular genetics & genomic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHeterozygous loss-of-function variants in the KMT2C gene were only recently recognized as a cause of neurodevelopmental disorder distinct from Kleefstra and Kabuki 1 syndromes. KMT2C-related neurodevelopmental disorder is characterized by developmental delay, intellectual disability, behavioral and psychiatric problems, seizures, craniofacial dysmorphism, and other comorbidities. Here we describe detailed phenotypes of three additional patients with novel variants in the KMT2C gene. METHODS AND
resultsUsing exome sequencing, we found two heterozygous variants c.3212G>A, p.(Trp1071*) and c.13204_13205delinsA, p.(Cys4402Ilefs*11) leading to premature stop codon and one heterozygous missense variant c.6517C>T, p.(Pro2173Ser) in the KMT2C gene (NM_170606.3) in patients with unrecognized neurodevelopmental disorder. Our patients suffer from developmental delay, speech delay, autism spectrum disorder, cognitive impairment, seizures, and/or craniofacial dysmorphism.
conclusionAfter detailed phenotype analysis and by comparison with previous reports, we found that our patients have very similar phenotypes as described before and thus further extend the list of KMT2C causal variants. Therefore, we believe that they fit into these previously described phenotypes of KMT2C-related Kleefstra syndrome 2 as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.